head-to-head comparative trial’s two-year outcomes of the Evolut transfemoral transcatheter aortic valve replacement (TAVR) ...

Medtronic plc MDT recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN (“SMART”) Trial results at the Cardiovascular Research Technologies (“CRT”) 2025 conference in Washington, D.C.

Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...

Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...

Medtronic plc released positive results from a two-year trial of Evolut TAVR that demonstrated superior valve performance in patients with small aortic annuli.

"The two-year results highlight the continued superior performance of the Evolut TAVR valve in these patients. While we would not yet expect to see a significant difference in the composite ...

The two-year results highlighted the continued superior performance of the Evolut TAVR valve in patients with a small aortic annulus. These results will be followed to assess long-term outcomes.

In the international, multi-centre trial, the Evolut TAVR demonstrated “continued superior” valve performance, according to bioprosthetic valve dysfunction (BVD) measurements. In addition ...

"The two-year results highlight the continued superior performance of the Evolut TAVR valve in these patients. While we would not yet expect to see a significant difference in the composite clinical ...